Theodore Pincus to Endpoint Determination
This is a "connection" page, showing publications Theodore Pincus has written about Endpoint Determination.
Connection Strength
0.651
-
An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
Score: 0.290
-
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S82-93.
Score: 0.135
-
Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care. Bull NYU Hosp Jt Dis. 2011; 69(2):104-10.
Score: 0.097
-
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.
Score: 0.078
-
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13.
Score: 0.025
-
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86.
Score: 0.025